AUM Biosciences Pte Ltd.
🇸🇬Singapore
- Country
- 🇸🇬Singapore
- Ownership
- Subsidiary
- Established
- 2018-01-01
- Employees
- 11
- Market Cap
- -
MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- AUM Biosciences Pte Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT05462236
- Locations
- 🇦🇺
Ballarat Oncology and Haematology, Wendouree, Victoria, Australia
🇦🇺Pindara Private Hospital, Gold Coast Cancer Care, Benowa, Queensland, Australia
🇦🇺Cabrini Hospital, Malvern, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath